Y mAbs Therapeutics company info

What does Y mAbs Therapeutics do?
Y-mAbs Therapeutics (NASDAQ:YMAB) is a biopharmaceutical company focused on the development and commercialization of novel antibody-based therapies for the treatment of cancer and rare diseases. Their operations span from early-stage research to the commercialization of their products, aiming to improve patient outcomes with cutting-edge treatments. Y mAbs Therapeutics is dedicated to advancing a diverse pipeline of therapeutic candidates, including projects targeting pediatric cancers and other life-threatening conditions. Their objective is to translate groundbreaking scientific research into transformative therapies for patients who currently have limited treatment options, emphasizing a commitment to innovation and patient care in the medical field.
Y mAbs Therapeutics company media
Company Snapshot

Is Y mAbs Therapeutics a public or private company?


How many people does Y mAbs Therapeutics employ?


What sector is Y mAbs Therapeutics in?

pie chart
Health Care

Where is the head office for Y mAbs Therapeutics?

location pin
Head Office
New York, United States

What year was Y mAbs Therapeutics founded?

founded flag
Year Founded
What does Y mAbs Therapeutics specialise in?
/Cancer Immunotherapies /Pediatric Oncology /Antibody Therapies /Clinical Trials /Biopharmaceutical Products /Research Development

What are the products and/or services of Y mAbs Therapeutics?

Overview of Y mAbs Therapeutics offerings
DANYELZA, an FDA-approved treatment for pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in combination with granulocyte-macrophage colony-stimulating factor.
Omburtamab, an investigational radioimmunotherapy under development for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma and other potential indications.
GD2-GD3 Vaccine, an investigational cancer vaccine aimed at stimulating the immune system to attack neuroblastoma cells, currently in early clinical development.
naxitamab, an investigational GD2-directed antibody being evaluated for various types of cancers, including osteosarcoma and other solid tumors, in combination with other therapies.
SADA technology, a proprietary drug development platform designed to create next-generation antibody-drug conjugates and radioimmunotherapies with potential applications across multiple cancer types.
GD2-BiTE, an investigational bispecific T-cell engager targeting GD2-positive cancers, leveraging the immune system to destroy cancer cells, currently in pre-clinical development.

Who is in the executive team of Y mAbs Therapeutics?

Y mAbs Therapeutics leadership team
  • Mr. Thomas  Gad
    Mr. Thomas Gad
    Founder, Chief Business Officer & Vice Chairman
  • Mr. Bo  Kruse
    Mr. Bo Kruse
    Executive VP, Secretary, Treasurer & CFO
  • Ms. Susan  Smith
    Ms. Susan Smith
    Senior VP & Chief Commercial Officer
  • Mr. Michael  Rossi
    Mr. Michael Rossi
    CEO, President & Director
  • Mr. Joris Wiel Jan Wilms
    Mr. Joris Wiel Jan Wilms
    Senior VP & COO
  • Dr. Torben  Lund-Hansen M.Sc., Ph.D.
    Dr. Torben Lund-Hansen M.Sc., Ph.D.
    Senior VP & CTO
  • Dr. Steen  Lisby M.D., M.Sc.
    Dr. Steen Lisby M.D., M.Sc.
    Senior VP & Chief Scientific Officer
  • Ms. Courtney  Dugan
    Ms. Courtney Dugan
    Vice President of Investor Relations